Background: Pancreatic adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. However, rapid expansion of biomarker-directed therapies, immunotherapy, and novel treatment modalities has created an increasingly complex clinical trial landscape...
Laura Radoš, Sara Matulić Čubranić, M. Golčić et al.· Pharmaceuticals· 0 citations
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin-angiotensin-aldosterone s...
C. Antza, Andrej Belančić, Jens Jordan et al.· British Journal of Clinical...· 0 citations
The clinical efficacy and real-world effectiveness of approved disease-modifying therapies, including nusinersen, onasemnogene abeparvovec, and risdiplam are summarized, underscoring significant improvements in survival, motor milestones, and quality of life, particularly with early treatment initiation.
Andrej Belančić, Elvira Meni Maria Gkrinia, Yun-Wah Lam et al.· Frontiers in Pharmacology· 0 citations
Declining DALYs, YLLs, and indirect costs suggest improving melanoma outcomes in Croatia, potentially reflecting earlier detection and therapeutic innovation, and underscore the importance of sustained investment in integrated melanoma control strategies.
Goran Benčina, Marija Buljan, B. Benčina et al.· Expert review of pharmacoeco...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
